Patents Assigned to New England Medical Center Hospital
-
Patent number: 9044424Abstract: The present invention provides methods for modification and regulation of glucose metabolism by administering to an animal a therapeutically effective amount of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to increase the plasma half-life of glucagon-like peptide 1 (GLP-1) but not sufficient to suppress the immune system of the animal.Type: GrantFiled: July 25, 2013Date of Patent: June 2, 2015Assignees: 1149336 Ontario, Inc., New England Medical Center Hospitals. Inc., Trustees of Tufts CollegeInventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Publication number: 20140178472Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.Type: ApplicationFiled: July 25, 2013Publication date: June 26, 2014Applicants: Trustees of Tufts College, 1149336 Ontario, Inc., New England Medical Center Hospitals, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Patent number: 8513190Abstract: The present invention provides methods for modification and regulation of type II diabetes by administering to an animal a therapeutically effective amount of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to treat type II diabetes but not sufficient to suppress the immune system of the animal.Type: GrantFiled: November 16, 2011Date of Patent: August 20, 2013Assignees: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Publication number: 20130095036Abstract: The present invention features noninvasive methods for diagnosing IgA or IgM kidney disorders, such as IgA nephropathy, Henoch-Schönlein purpura, and IgM nephropathy, in a mammal. The invention also features compositions and kits useful in diagnosing these disorders.Type: ApplicationFiled: April 4, 2012Publication date: April 18, 2013Applicants: New England Medical Center Hospitals, Inc., RQ Bioscience, Inc.Inventors: Robert Qiu, Jiazhou Qiu, Andrew G. Plaut
-
Patent number: 8318669Abstract: The present invention provides methods for modification and regulation of glucagon-like peptide 1 (GLP-1) metabolism by administering therapeutically effective amounts of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to inhibit DPIV proteolysis of GLP-1 but not sufficient to suppress the immune system of the animal.Type: GrantFiled: November 9, 2010Date of Patent: November 27, 2012Assignees: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Publication number: 20120165252Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.Type: ApplicationFiled: November 16, 2011Publication date: June 28, 2012Applicants: Trustees of Tufts College, 1149336 Ontario, Inc., New England Medical Center Hospitals, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Publication number: 20110177957Abstract: The present invention provides for certain polynucleotide sequences that have been correlated to AMD. These polynucleotides are useful as diagnostics, and are preferably used to fabricate an array, useful for screening patient samples. The array is used as part of a laboratory information management system, to store and process additional patient information in addition to the patient's genomic profile. As described herein, the system provides an assessment of the patient's risk for developing AMD, risk for disease progression, and the likelihood of disease prevention based on patient controllable factors.Type: ApplicationFiled: April 17, 2009Publication date: July 21, 2011Applicant: Tufts Medical Center, Inc., (f/k/a/ New England Medical Center Hospitals, Inc.)Inventors: Johanna M. Seddon, Mark Daly
-
Publication number: 20110172149Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.Type: ApplicationFiled: November 9, 2010Publication date: July 14, 2011Applicants: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker
-
Patent number: 7829530Abstract: One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal but not sufficient to suppress the animal's immune system.Type: GrantFiled: November 26, 2008Date of Patent: November 9, 2010Assignees: Trustees of Tufts College, New England Medical Center Hospitals, 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker
-
Patent number: 7723467Abstract: The invention features an antimicrobial composition comprising a substance P peptide and methods of inhibiting growth of a microorganism by contacting the microorganism with a substance P peptide. Bacterial and fungal pathogens are inhibited by the substance P compositions.Type: GrantFiled: July 13, 2005Date of Patent: May 25, 2010Assignee: New England Medical Center Hospitals, Inc.Inventors: Andrzej W. Lipkowski, Daniel B. Carr
-
Patent number: 7498311Abstract: A method for treating migraine in non-epileptic subjects which involves administering to subjects an effective amount of a pharmaceutical composition comprising a sulfamate of the following formula:Type: GrantFiled: January 6, 2006Date of Patent: March 3, 2009Assignee: New England Medical Center Hospitals, Inc.Inventors: Bruce L. Ehrenberg, Anita K. Wagner
-
Publication number: 20080300193Abstract: The present invention includes peptidomimetic compound compositions and methods of making and using peptidomimetic compounds to modulate the activity of a peptide receptor for the treatment of one or more of hyperglycemia, insulin resistance, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia or other symptoms that relate to the function of the targeted receptor. The peptidomimetic includes an oligo-benzamide compound having at least three optionally substituted benzamides.Type: ApplicationFiled: March 13, 2008Publication date: December 4, 2008Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, NEW ENGLAND MEDICAL CENTER HOSPITALS, INC.Inventors: Jung-Mo Ahn, Martin Beinborn
-
Patent number: 7459428Abstract: One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal.Type: GrantFiled: July 17, 2006Date of Patent: December 2, 2008Assignees: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker
-
Publication number: 20070110710Abstract: Methods and compositions are provided for the treatment of an autoimmune disease. The methods include administering immunoregulatory T cells (Tregs) to patients. The therapeutic Tregs can express the CD25, CD4, and/or ICOS antigens. The therapeutic T cells can be CD25+ ICOS+, CD4+ICOS+, and/or CD25+ CD4+ ICOS+, and they can be provided by a donor.Type: ApplicationFiled: November 5, 2004Publication date: May 17, 2007Applicant: NEW ENGLAND MEDICAL CENTER HOSPITALS, INC.Inventors: Francine Foss, Yong Xie
-
Patent number: 7142634Abstract: A radiation field detection system, for use with a radiating device, includes a radiation detector configured to receive radiation and to provide radiation strength indicia of amounts of radiation received, a positioning mechanism connected to the radiation detector and configured to physically move the radiation detector, and a processor coupled to the positioning mechanism and coupled to the radiation detector to receive the radiation strength indicia, the processor being configured to: actuate the positioning mechanism to move the radiation detector to desired locations within a radiation field produced by the radiating device; analyze the radiation strength indicia from the radiation detector; correlate positions of the radiation detector with corresponding amounts of received radiation; determine a first location of maximum detected radiation; and determine a first relationship between the first location of maximum detected radiation and a second location of maximum radiation.Type: GrantFiled: January 29, 2004Date of Patent: November 28, 2006Assignee: New England Medical Center Hospitals, Inc.Inventors: Mark J. Engler, Mark J. Rivard
-
Patent number: 7122655Abstract: The present invention relates to screening methods that make use of Myosin Phosphatase-Rho interacting Protein (M-RIP) for the identification of novel therapeutics for hypertension and hypertensive conditions. Also disclosed are methods for treating or preventing hypertension or hypertensive conditions by administering to a mammal a therapeutically effective amount of an agent that reduces the level or activity of M-RIP. According to this invention, the agent decreases contractile and increases relaxant effects of smooth muscle cells, ultimately decreasing the systemic blood pressure of a mammal. For example, the agent may reduce binding of M-RIP to myosin phosphatase, RhoA, or both.Type: GrantFiled: November 17, 2003Date of Patent: October 17, 2006Assignee: New England Medical Center Hospital, Inc.Inventors: Michael E. Mendelsohn, Howard K. Surks
-
Patent number: 7118524Abstract: The present invention discloses a methodology for the characterization and determination of mixed-field dosimetry for 252Cf Applicator Tube (AT)-type medical sources, utilizing ionization chambers, GM counters, and Monte Carlo methods. Unlike the previous methodologies, the present invention discloses a specification of dose to muscle, rather than dose to water, for clinical dosimetry of 252Cf medical sources. A dosimetry protocol, similar to that utilized for ICRU-45, with parameters determined specifically for 252Cf brachytherapy is disclosed. Neutron isodose distributions and data necessary for clinical implementation of 252Cf AT sources are also disclosed herein. Additionally, novel methods for the encapsulation, storage, and delivery/implantation of 252Cf radionuclide sources are disclosed.Type: GrantFiled: April 22, 2003Date of Patent: October 10, 2006Assignee: New England Medical Center Hospitals, Inc.Inventor: Mark J. Rivard
-
Patent number: 7033746Abstract: Disclosed is substantially pure NES1 polypeptide and purified DNA, vectors, and cells encoding that polypeptide. Also disclosed are methods for carcinoma detection and treatment using the NES1 sequence.Type: GrantFiled: December 12, 2001Date of Patent: April 25, 2006Assignee: New England Medical Center Hospitals, Inc.Inventor: Vimla Band
-
Patent number: 7024238Abstract: In one aspect, a method of detecting ischemia within the brain of a patient. The method includes assigning a first value to a first signal generated by a tissue on the right-hand side of the body and assigning a second value to a second signal generated by a tissue on the left-hand side of the body. The method also includes comparing the first value and the second value. The difference between the first value and the second value indicates that ischemia is present within the patient's brain.Type: GrantFiled: April 16, 2004Date of Patent: April 4, 2006Assignee: New England Medical Center Hospitals, Inc.Inventor: Peter Bergethon
-
Patent number: 7018396Abstract: A method of selectively enhancing photothermal sebaceous gland disruption and treatment of acne is disclosed. The method provides for alleviation of the acne symptoms as well as preventing acne recurrence and new acne from occurring.Type: GrantFiled: August 7, 2001Date of Patent: March 28, 2006Assignee: New England Medical Center Hospitals, Inc.Inventors: Rafael A. Sierra, Mirko Mirkov, Kathleen I. McMillan, Jennifer R. Lloyd